查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
带状疱疹治疗的全球市场:市场规模 - 各给药途径，各治疗类型，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1174974

带状疱疹治疗的全球市场:市场规模 - 各给药途径，各治疗类型，各流通管道，各地区展望，竞争策略，各市场区隔预测(～2032年)

Herpes Zoster Treatment Market Size- By Route Of Administration, By Treatment Type, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 238 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球带状疱疹治疗的市场规模，至2032年达到3亿2,000万美元，预计以3.68％的年复合成长率成长。

由于COVID-19影响，医院和医疗机关非选择性的治疗延期，不过，带状疱疹治疗市场预计慢慢恢復。

本报告提供全球带状疱疹治疗市场相关调查，市场动态，市场变数与展望，各给药途径、治疗类型、流通管道、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球带状疱疹治疗市场上COVID-19的影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球带状疱疹治疗市场:各给药途径(2019年～2032年(100万美元))

  • 口服
  • 局部

第7章 全球带状疱疹治疗市场:各治疗类型(2019年～2032年(100万美元))

  • 抗病毒药物
  • 抗发炎剂
  • 其他

第8章 全球带状疱疹治疗市场:各流通管道(2019年～2032年(100万美元))

  • 药妆店、零售药局
  • 医院药局
  • 线上供应商

第9章 全球带状疱疹治疗市场:各地区(2019年～2032年(100万美元))

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第10章 企业简介

  • Abbott Laboratory
    • 企业概要
    • 财务展望
    • 产品概要
    • 最近的开发
  • Bausch Health
  • Camber Pharmaceuticals
  • Cipla Inc.
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Merck
  • Novaritis AG
  • GoodRx
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: HLCA2221

Global Herpes Zoster Treatment Market Overview:

According to SPER Market Research, the Global Herpes Zoster Treatment Market is estimated to reach USD 0.32 billion by 2032 with a CAGR of 3.68%.

The varicella-zoster virus is the cause of the viral illness known as herpes zoster (shingles). It often starts as a burning, itchy skin rash that spreads to the rest of the body, causing blisters on the back, chest, and face. Pain along the afflicted dermatome is usually the first symptom, which is followed in 2-3 days by an expanded vesicular eruption. Lymph nodes, fever, chills, and headache are among the symptoms. There may also be itching, raised spots on the skin, localised redness, a stabbing or shooting pain, tingling or burning sensation in or beneath the skin, or an upset stomach.

Impact of COVID-19 on the Global Herpes Zoster Treatment Market

In order to prevent cross-contamination, fewer procedures and patients have visited hospitals. This has a detrimental effect on the market for herpes zoster medications. Additionally, a reduction in staff was made to care for patients receiving herpes zoster therapy as a result of the transfer in medical personnel to treat COVID-19-infected individuals. As a result, non-elective procedures were delayed at several hospitals and healthcare institutes. The market for herpes zoster medications, however, is anticipated to gradually rebound after the epidemic.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Route Of Administration, By Treatment Type, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Abbott Laboratory, Bausch Health, Camber Pharmaceuticals, Cipla Inc., Eli Lilly and Co., GlaxoSmithKline PLC, Merck, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Global Herpes Zoster Treatment Market Segmentation:

  • By Route Of Administration: Based on the Route Of Administration, Global Herpes Zoster Treatment Market is segmented as; Oral and Topical.
  • By Treatment Type: Based on the Treatment Type, Global Herpes Zoster Treatment Market is segmented as; Antiviral Medications, Anti-inflammatory Medications and Other.
  • By Distribution Channel: Based on the Distribution Channel, Global Herpes Zoster Treatment Market is segmented as; Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Provider.
  • By Region: In terms of revenue, North America led the world market for treating herpes zoster and is predicted to maintain that position. This is a result of the presence of important actors throughout the region and the accessibility of cutting-edge healthcare facilities with skilled medical personnel.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Herpes Zoster Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Herpes Zoster Treatment Market, By Route Of Administration, 2019-2032 (USD Million)

  • 6.1. Oral
  • 6.2. Topical

7. Global Herpes Zoster Treatment Market, By Treatment Type, 2019-2032 (USD Million)

  • 7.1. Antiviral Medication
  • 7.2. Anti-inflammatory Medications
  • 7.3. other

8. Global Herpes Zoster Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 8.1. Drug Stores & Retail Pharmacies
  • 8.2. Hospital Pharmacies
  • 8.3. Online Provider

9. Global Herpes Zoster Treatment Market, By Region, 2019-2032 (USD Million)

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 United Kingdom
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Middle East & Africa
    • 9.5.1 Kingdom of Saudi Arabia
    • 9.5.2 United Arab Emirates
    • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

  • 10.1 Abbott Laboratory
    • 10.1.1 Company details
    • 10.1.2 Financial outlook
    • 10.1.3 Product summary
    • 10.1.4 Recent developments
  • 10.2 Bausch Health
    • 10.2.1 Company details
    • 10.2.2 Financial outlook
    • 10.2.3 Product summary
    • 10.2.4 Recent developments
  • 10.3 Camber Pharmaceuticals
    • 10.3.1 Company details
    • 10.3.2 Financial outlook
    • 10.3.3 Product summary
    • 10.3.4 Recent developments
  • 10.4 Cipla Inc.
    • 10.4.1 Company details
    • 10.4.2 Financial outlook
    • 10.4.3 Product summary
    • 10.4.4 Recent developments
  • 10.5 Eli Lilly and Co.
    • 10.5.1 Company details
    • 10.5.2 Financial outlook
    • 10.5.3 Product summary
    • 10.5.4 Recent developments
  • 10.6 GlaxoSmithKline PLC
    • 10.6.1 Company details
    • 10.6.2 Financial outlook
    • 10.6.3 Product summary
    • 10.6.4 Recent developments
  • 10.7 Merck
    • 10.7.1 Company details
    • 10.7.2 Financial outlook
    • 10.7.3 Product summary
    • 10.7.4 Recent developments
  • 10.8 Novaritis AG
    • 10.8.1 Company details
    • 10.8.2 Financial outlook
    • 10.8.3 Product summary
    • 10.8.4 Recent developments
  • 10.9 GoodRx
    • 10.9.1 Company details
    • 10.9.2 Financial outlook
    • 10.9.3 Product summary
    • 10.9.4 Recent developments
  • 10.10 Pfizer Inc.
    • 10.10.1 Company details
    • 10.10.2 Financial outlook
    • 10.10.3 Product summary
    • 10.10.4 Recent developments
  • 10.11 Teva Pharmaceutical Industries Ltd.
    • 10.11.1 Company details
    • 10.11.2 Financial outlook
    • 10.11.3 Product summary
    • 10.11.4 Recent developments